---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003174"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T11:58:16.359853+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptose's TUS+VEN+AZA triplet data selected for oral presentation at EHA 2025 Congress

## Summary
- Data from TUSCANY Phase 1/2 trial of tuspetinib (TUS) + venetoclax + azacitidine in newly diagnosed AML accepted for oral presentation at EHA 2025 (June 12-15, Milan).
- Oral presentation will include updated safety, complete remission, and MRD data at 40 mg and 80 mg dose levels with longer follow-up.
- Prior data showed safety and complete remissions across diverse mutations including TP53-mutated and FLT3-wildtype patients.
- TUS+VEN+AZA is being developed as mutation-agnostic frontline therapy for AML patients ineligible for induction chemotherapy.
- Anticipated enrollment of 18-24 patients in TUSCANY trial by mid-late 2025.

## SEC filing metadata
- accession: 0001171843-25-003174
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325003174/0001171843-25-003174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325003174/f8k_051425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003174
- JSON: https://secwatch.observer/filing/0001171843-25-003174.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.